The report "Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027", is projected to reach USD 2.5 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 6.7% during the forecast period. Pain is the physiological term to describe the chemical processes that are at work in the body that receive a stimulus, modify it, and transfer it to the brain for interpretation and reaction. The stimulus can be physical, temperature, chemical, or inflammatory damage to tissues. In veterinary practices, pain management is achieved through analgesic drugs and devices.
Browse 299 market data Tables and 56 Figures spread through 298 Pages and in-depth TOC on "Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/veterinary-pain-management-market-96167677.html
In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
“NSAIDs is expected to witness the fastest growth veterinary pain management market by drug type during the forecast period.”
The veterinary pain management market is segment into NSAIDs, opioids, local anesthetics, alpha-2 agonists, disease-modifying osteoarthritis drugs, and other drugs on the basis of drug type. In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market. The large share of this segment can be attributed to the widespread adoption of NSAIDs in a wide range of applications due to the low cost of these drugs.
“Oral segment is expected to witness the fastest growth in the forecast period.”
The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration. The oral segment accounted for the largest share of the veterinary pain management drugs market by route of administration in 2021. The oral administration segment held the largest share because orally administered drugs are convenient, easy to store, do not require special training, and are affordable.
“ Joint pain accounted for the largest share of by veterinary pain management market by application in 2021”
Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications. The joint pain segment accounted for the largest share of the veterinary pain management market in 2021. The large share of this segment can be attributed to the growing geriatric pet population, the growing prevalence of osteoarthritis and musculoskeletal disorders, and the increasing population of obese and overweight pets.
“Asia Pacific region is expected to witness the fastest growth during the forecast period”
On the basis of region, the veterinary pain management market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period and countries such as Japan, China, and India are expected to provide significant growth opportunities for market players. These countries have a large livestock population, as well as a growing trend of pet ownership.
Key Market Players :
The prominent players in the veterinary pain management market are Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Dechra Pharmaceuticals (UK), Vetoquinol (France), SeQuent Scientific Limited (India), Norbrook Laboratories Limited (Ireland), Ceva Santé Animale (France), Chanelle Pharma (Ireland), and K-Laser USA (US). New product launches and acquisitions were the major strategies adopted by these payers to maintain their positions in the veterinary pain management market.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441